Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma


Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma




The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma. The appropriate dose determined from the first part of the study will be used in the second part of the study to assess disease response in 6 different types of lymphoma patients.

Study Status: Recruiting


Condition Intervention Phase
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: PCI-24781 Phase 1/Phase 2

Verified by Pharmacyclics August, 2008

Sponsored by: Pharmacyclics
Information provided by: Pharmacyclics identifier: NCT00724984

Study Type: Interventional

Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

The Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site